2022
Re-evaluating the health impact and cost-effectiveness of tuberculosis preventive treatment for modern HIV cohorts on antiretroviral therapy: a modelling analysis using data from Tanzania
Zhu J, Lyatuu G, Sudfeld CR, Kiravu A, Sando D, Machumi L, Minde J, Chisonjela F, Cohen T, Menzies NA. Re-evaluating the health impact and cost-effectiveness of tuberculosis preventive treatment for modern HIV cohorts on antiretroviral therapy: a modelling analysis using data from Tanzania. The Lancet Global Health 2022, 10: e1646-e1654. PMID: 36240830, PMCID: PMC9553191, DOI: 10.1016/s2214-109x(22)00372-2.Peer-Reviewed Original ResearchConceptsIsoniazid preventive therapyCD4 cell countAntiretroviral therapyCell countART cohortAverage CD4 cell countHigher CD4 cell countsLarge HIV treatment programHealth impactsTuberculosis preventive treatmentHIV treatment programsLifetime costsIncremental lifetime costLifetime health benefitsCourse of infectionGreater health gainsLong-term healthART initiationTreat guidelinesHIV cohortPreventive therapyTuberculosis riskUS National InstitutesHIV programsSubgroup analysis
2020
High-resolution estimates of tuberculosis incidence among non-U.S.-born persons residing in the United States, 2000–2016
Hill AN, Cohen T, Salomon JA, Menzies NA. High-resolution estimates of tuberculosis incidence among non-U.S.-born persons residing in the United States, 2000–2016. Epidemics 2020, 33: 100419. PMID: 33242759, PMCID: PMC7808561, DOI: 10.1016/j.epidem.2020.100419.Peer-Reviewed Original ResearchConceptsIncidence risk ratioTuberculosis incidence rateIncidence rateTuberculosis riskTuberculosis casesNational Tuberculosis Surveillance SystemTuberculosis prevention effortsNew tuberculosis casesLow incidence rateTuberculosis Surveillance SystemBirth countryTuberculosis incidenceRisk ratioTuberculosis trendsHigh-income countriesYounger agePrevention effortsEffective targetingCohortEntry yearCommunity surveySurveillance systemRegression modelsAgeUnited States
2015
Identifying Hotspots of Multidrug-Resistant Tuberculosis Transmission Using Spatial and Molecular Genetic Data
Zelner JL, Murray MB, Becerra MC, Galea J, Lecca L, Calderon R, Yataco R, Contreras C, Zhang Z, Manjourides J, Grenfell BT, Cohen T. Identifying Hotspots of Multidrug-Resistant Tuberculosis Transmission Using Spatial and Molecular Genetic Data. The Journal Of Infectious Diseases 2015, 213: 287-294. PMID: 26175455, PMCID: PMC4690150, DOI: 10.1093/infdis/jiv387.Peer-Reviewed Original ResearchConceptsMDR tuberculosisDrug susceptibilityTuberculosis casesMultidrug-resistant tuberculosis (MDR-TB) transmissionCulture-confirmed diseaseHealth Center areaProspective cohort studyCapita incidenceHousehold contactsCohort studyTuberculosis riskTuberculosis transmissionSymptomatic individualsHigh riskPositive culturesNumber tandem repeatRiskEtiology
2014
Incidence of multidrug-resistant tuberculosis disease in children: systematic review and global estimates
Jenkins HE, Tolman AW, Yuen CM, Parr JB, Keshavjee S, Pérez-Vélez CM, Pagano M, Becerra MC, Cohen T. Incidence of multidrug-resistant tuberculosis disease in children: systematic review and global estimates. The Lancet 2014, 383: 1572-1579. PMID: 24671080, PMCID: PMC4094366, DOI: 10.1016/s0140-6736(14)60195-1.Peer-Reviewed Original ResearchConceptsMultidrug-resistant tuberculosisMultidrug-resistant tuberculosis diseaseTreatment-naive adultsMultidrug-resistant diseaseTuberculosis diseaseTuberculosis incidenceGlobal incidenceSystematic reviewCases of tuberculosisHarvard Medical SchoolGlobal tuberculosis incidenceGlobal annual incidenceTuberculosis riskAnnual incidencePatient groupUS National InstitutesWomen's HospitalInclusion criteriaInternal medicineNew diagnostic instrumentDisease riskTuberculosisIncidenceDiseaseHealth equity
2011
Risk Factors for Tuberculosis After Highly Active Antiretroviral Therapy Initiation in the United States and Canada: Implications for Tuberculosis Screening
Sterling TR, Lau B, Zhang J, Freeman A, Bosch RJ, Brooks JT, Deeks SG, French A, Gange S, Gebo KA, Gill M, Horberg MA, Jacobson LP, Kirk GD, Kitahata MM, Klein MB, Martin JN, Rodriguez B, Silverberg MJ, Willig JH, Eron JJ, Goedert JJ, Hogg RS, Justice AC, McKaig RG, Napravnik S, Thorne J, Moore RD. Risk Factors for Tuberculosis After Highly Active Antiretroviral Therapy Initiation in the United States and Canada: Implications for Tuberculosis Screening. The Journal Of Infectious Diseases 2011, 204: 893-901. PMID: 21849286, PMCID: PMC3156918, DOI: 10.1093/infdis/jir421.Peer-Reviewed Original ResearchConceptsActive antiretroviral therapy (HAART) initiationAntiretroviral therapy initiationInjection drug useHIV-1 RNAHuman immunodeficiency virusHAART initiationTuberculosis riskBaseline CD4Therapy initiationMale sexNonwhite raceHispanic ethnicityDrug useBaseline HIV-1 RNAMonths of HAARTLow-incidence settingsProportional hazards modelActive tuberculosisLymphocyte countParametric survival modelsTuberculosis screeningImmunodeficiency virusBlack raceLymphocytes/Risk factors
1998
Tuberculosis Risk in Funeral Home Employees
Gershon R, Vlahov D, Escamilla-Cejudo J, Badawi M, McDiarmid M, Karkashian C, Grimes M, Comstock G. Tuberculosis Risk in Funeral Home Employees. Journal Of Occupational And Environmental Medicine 1998, 40: 497-503. PMID: 9604188, DOI: 10.1097/00043764-199805000-00014.Peer-Reviewed Original ResearchConceptsTuberculin skin testTuberculin skin testingSkin testingSkin testAnnual tuberculin skin testingReactive tuberculin skin testHome employeesPast historyRisk assessment questionnaireTuberculin reactivityTuberculosis infectionTuberculosis riskTuberculosis casesTuberculosis preventionInfected individualsStudy participantsClose contactConvenience sampleRespiratory protectionJob categoriesAgeRiskRisk assessment studiesNumber of yearsHistory
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply